Exploring practical experience with different treatments in NSCLC patients with MET-deregulated: a retrospective analysis from the real world
Abstract Background Mesenchymal to epithelial transition factor (MET) dysregulation in non-small-cell-lung-cancer (NSCLC) is understudied, with scant data on treatment outcomes. Methods We retrospectively examined 160 NSCLC patients: 125 with primary MET mutations (further classified into MET exon 1...
Saved in:
Main Authors: | Mengmeng Li, Jiuyan Huang, Ruyue Xing, Xinyang Du, Chunhua Wei, Huijuan Wang |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2025-01-01
|
Series: | BMC Pulmonary Medicine |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12890-024-03437-4 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Cost-effectiveness analysis of gumarontinib versus savolitinib for the treatment of advanced or metastatic NSCLC with MET exon 14 skipping mutations in China using partitioned survival model
by: Gang Fang, et al.
Published: (2025-01-01) -
Epithelial mesenchymal transition in human menstruation and implantation
by: Hiroshi Uchida
Published: (2024-08-01) -
Real-world studies of crizotinib in patients with ROS1-positive non-small-cell lung cancer: experience from China
by: Hua Zhong, et al.
Published: (2024-12-01) -
Transcription factor A, mitochondrial promotes lymph node metastasis and lymphangiogenesis in epithelial ovarian carcinoma
by: Wubuli Reziwanguli, et al.
Published: (2025-02-01) -
MYH9 promotes malignant progression of glioma cells through regulating β-catenin stability via epithelial-mesenchymal transition signaling pathway
by: Zigui Chen, et al.
Published: (2025-02-01)